Kept an ocean away from its sci­en­tif­ic ad­vi­sors, Shang­hai's Elpi­science keeps up the clin­i­cal progress, re­fu­els for its I/O pipeline

When Elpi­science pooled $100 mil­lion for its Se­ries B in late 2019, CEO Dar­ren Ji promised to move what he de­scribed as one of the broad­est im­muno-on­col­o­gy pipelines swift­ly through the clin­ic in both the US and Chi­na.

Then a pan­dem­ic got in the way — but not by much. The Shang­hai-based biotech man­aged to keep test­ing its 4-1BB/PD-L1 drug, get an OX40 ag­o­nist cleared for clin­i­cal tri­als (nab­bing a col­lab­o­ra­tion with Jun­shi in the process), while in-li­cens­ing a Phase I bis­pe­cif­ic from Cal­i­for­nia’s TRI­GR Ther­a­peu­tics.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER